SM 020
Alternative Names: SM-020Latest Information Update: 21 Aug 2024
At a glance
- Originator SeylanMED
- Developer DermBiont
- Class Skin disorder therapies; Small molecules
- Mechanism of Action Proto-oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Basal cell cancer; Seborrhoeic keratosis; Squamous cell cancer
Most Recent Events
- 15 Aug 2024 DermBiont plans to seek Fast Track designation in basal cell carcinoma (BCC) and prevention of BCC in Gorlin syndrome patients
- 15 Aug 2024 DermBiont plans to seek Orphan Drug designation in basal cell carcinoma (BCC) and prevention of BCC in Gorlin syndrome patients
- 15 Aug 2024 Efficacy and safety data from a phase IIa trial in Basal cell carcinoma released by DermBiont